78756-28-2

Basic information

• Product Name: 1,4-DIHYDRO-2H-THIENO[3,2-D][1,3]OXAZINE-2,4-DIONE
• Synonyms: 1,4-Dihydro-2,4-dioxo-2H-thieno[3,2-d][1,3]oxazine;2H-Thieno[3,2-d][1,3]oxazine-2,4(1H)-dione
• CAS NO: 78756-28-2
• Molecular Formula: C₆H₃NO₃S
• Molecular Weight: 169.1597
• Mol File: 78756-28-2.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 1,4-DIHYDRO-2H-THIENO[3,2-D][1,3]OXAZINE-2,4-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-DIHYDRO-2H-THIENO[3,2-D][1,3]OXAZINE-2,4-DIONE(78756-28-2)
• EPA Substance Registry System: 1,4-DIHYDRO-2H-THIENO[3,2-D][1,3]OXAZINE-2,4-DIONE(78756-28-2)

Safety Data

• Hazardous Substances Data: 78756-28-2(Hazardous Substances Data)

Usage

General Description

1,4-Dihydro-2H-thieno[3,2-d][1,3]oxazine-2,4-dione is a chemical compound with a complex ring structure containing oxygen, nitrogen, and sulfur. It is also known as rhodanine and has applications in pharmaceutical and agricultural industries due to its bioactive and pesticidal properties. Rhodanine derivatives have been studied for their potential antitumor, antiviral, and antibacterial activities, making them of interest for drug development. Additionally, rhodanine compounds have been investigated for their ability to inhibit certain enzymes and biological pathways, making them potentially valuable in therapeutic interventions for diseases such as cancer and neurodegenerative disorders. Overall, 1,4-Dihydro-2H-thieno[3,2-d][1,3]oxazine-2,4-dione is a versatile compound with diverse applications in medicine and agriculture.

Upstream product

• 75-44-5 phosgene 
• 55341-87-2 3-aminothiophene-2-carboxylic acid 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 118235-61-3 3-ethoxycarbonylamino-thiophene-2-carboxylic acid 
• 64615-13-0 3-Amino-2-thiophencarbonsaeure-methylester-hydrochlorid 
• 78756-27-1 sodium 3-aminothiophene-2-carboxylate 
• 71-36-3 butan-1-ol 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 503-38-8 trichloromethyl chloroformate 
• 1210469-45-6 potassium 3-aminothiophene-2-carboxylate 

Downstream Products

• 213390-51-3 3-(3-methylureido)thiophene-2-carboxylic acid 
• 213390-57-9 3-{[(benzyloxy)carbonyl]amino}thiophene-2-carboxylic acid 
• 231630-04-9 1-benzyl-2H-thieno[3,2-d][1,3]oxazine-2,4(1H)-dione 
• 934602-35-4 (S)-2-[(3-aminothiophene-2-carbonyl)amino]propionic acid 
• 934602-36-5 (S)-3-[3-(1-carboxyethyl)ureido]thiophene-2-carboxylic acid 
• 231630-06-1 3-(benzylamino)thiophene-2-carbonyl azide 
• 103979-61-9 1-(3-Methylamino-thiophen-2-yl)-3-phenyl-propane-1,3-dione 
• 103979-63-1 1-(3,4-Dimethoxy-phenyl)-3-(3-methylamino-thiophen-2-yl)-propane-1,3-dione 
• 158460-93-6 [3-(4-Bromo-2-fluoro-benzyl)-6-chloro-2,4-dioxo-3,4-dihydro-2H-thieno[3,2-d]pyrimidin-1-yl]-acetic acid ethyl ester 
• 686266-52-4 1-benzyl-7-methyl-2H-thieno[3,2-d][1,3]oxazine-2,4(1H)-dione 

Relevant articles and documents

IL4I1 INHIBITORS AND METHODS OF USE

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.

PYRIDOPYRIMIDINEDIONE DERIVATIVES

The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors

A series of thienopyridinone derivatives was designed and synthesized as inhibitors of checkpoint kinase 1 (Chk1). Most of them exhibited moderate to good Chk1 inhibitory activities. Among them, compounds 8q, 8t, and 8w with excellent Chk1 inhibitory activities (IC50 values of 4.05, 6.23, and 2.33 nM, respectively) displayed strong synergistic effects with melphalan, a DNA-damaging agent in the cell-based assay. Further kinase profiling indicated that compound 8t was highly selective against CDK2/cyclinA, Aurora A, and PKC.